Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07290569 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
A Phase 2 study of Plaque Psoriasis, sponsored by Oruka Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT07290569 is a Phase 2 study of Plaque Psoriasis that is actively recruiting participants, run by Oruka Therapeutics. The registered enrollment target is 160 participants, below the 412-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT07290569, a Phase 2 study of Plaque Psoriasis, is actively recruiting participants, sponsored by Oruka Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG ORKA-001
Study Locations (20)
Texas
- Oruka Therapeutics Investigative Site - Frisco
- Oruka Therapeutics Investigative Site - Houston
- Oruka Therapeutics Investigative Site - Webster
California
- Oruka Therapeutics Investigative Site - Los Angeles
- Oruka Therapeutics Investigative Site - Los Angeles
Ohio
- Oruka Therapeutics Investigative Site - Cleveland
- Oruka Therapeutics Investigative Site - Mason
Oregon
- Oruka Therapeutics Investigative Site - Portland
- Oruka Therapeutics Investigative Site - Portland
Arizona
- Oruka Therapeutics Investigative Site - Phoenix
Arkansas
- Oruka Therapeutics Investigative Site - North Little Rock
Florida
- Oruka Therapeutics Investigative Site - Coral Gables
Illinois
- Oruka Therapeutics Investigative Site - Rolling Meadows
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-12-03 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07290569
The ClinicalTrials.gov registry entry for NCT07290569 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 412-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (61% lower). The listed sponsor is Oruka Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07290569 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Texas, California, Ohio.
Frequently Asked Questions
What is clinical trial NCT07290569 about?
NCT07290569 is a clinical study titled "Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis". This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
What is the current status of trial NCT07290569?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2025-12-03. Estimated completion is 2028-12.
What conditions does trial NCT07290569 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT07290569?
The interventions under investigation include: Placebo (OTHER), ORKA-001 (DRUG).
Who is sponsoring clinical trial NCT07290569?
This trial is sponsored by Oruka Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07290569 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
RECRUITING · Phase 2
-
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression
COMPLETED · Phase 2
-
Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.